| 1.4 -0.02 (-1.41%) | 10-30 14:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.89 | 1-year : | 2.1 |
| Resists | First : | 1.62 | Second : | 1.79 |
| Pivot price | 1.45  |
|||
| Supports | First : | 1.34 | Second : | 1.11 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.51 |
| MA(100) : | 1.26  |
MA(250) : | 1.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 14.8 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 2.34 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALLR ] has closed above bottom band by 23.4%. Bollinger Bands are 35.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.48 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.41 - 1.42 | 1.42 - 1.43 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Mon, 27 Oct 2025
Allarity Therapeutics Advances Ovarian Cancer Study with 2X-121 - TipRanks
Mon, 22 Sep 2025
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
Thu, 18 Sep 2025
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - Investing News Network
Tue, 26 Aug 2025
Why Did Allarity Therapeutics Stock Double In Value Today? - Stocktwits
Tue, 26 Aug 2025
Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today? - TipRanks
Tue, 26 Aug 2025
Latest Developments in Allarity Therapeutics - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 458 (K) |
| Shares Short P.Month | 511 (K) |
| EPS | 5.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.1 % |
| Return on Equity (ttm) | -150.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | 0.24 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|